🚨#FDA Approval Update | A new approach to addressing muscle loss in #SMA The #FDA has approved #Isembyld (#apitegromab-mstn) for adults and children ≥2 years with spinal muscular atrophy (#SMA) who are receiving an SMN2-targeted treatment. As the first FDA-approved SMA therapy to directly target muscle loss, Isembyld is designed to complement existing approaches that target the underlying motor neuron loss. 📊In a Phase 3 trial, Isembyld 10 mg/kg showed improved motor function at 1 year, with 34.2% of patients achieving a clinically meaningful improvement vs. 13.5% with placebo. 🔬MedChemExpress offers apitegromab for research use only: medchemexpress.com/apitegrom… #SpinalMuscularAtrophy #RareDisease #NeuromuscularDisease #Biotech #DrugDevelopment #MedChemExpress